The Technical Analyst
PolyPid Ltd. [PYPD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
PolyPid Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.12% $4.48
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.42 mill |
| EPS: | -16.99 |
| P/E: | -0.260 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 1.654 mill |
| Avg Daily Volume: | 0.0034 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.260 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -0.260 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-4.39 (-197.97%) $-8.88 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.12 - 4.84 ( +/- 7.99%) |
| ATR Model: 14 days |
Forecast:
16:00 - $4.48
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.48 (-0.12% ) |
| Volume | 0.0009 mill |
| Avg. Vol. | 0.0034 mill |
| % of Avg. Vol | 26.71 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PYPD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PYPD
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-02-28 07:00:00 - Press Release
Polypid To Participate In Barclays 26th Annual Global Healthcare Conference
Petach tikva, israel, feb. 28, 2024 (globe newswire) -- polypid ltd. (nasdaq: pypd), (“polypid” or the “company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will participate in a fireside chat at the barclays 26th annual global healthcare conference taking place in miami beach, fl, march 12 – 14, 2024.
2024-02-14 07:00:00 - Press Release
Polypid Provides Corporate Update And Reports Fourth Quarter And Full Year 2023 Financial Results
More than 100 patients enrolled in ongoing shield ii phase 3 trial of d-plex 100 for the prevention of abdominal colorectal surgical site infections
2024-02-12 07:00:00 - Press Release
Polypid Announces Enrollment Of The 100th Patient In The Ongoing Shield Ii Phase 3 Trial
Approximately 40 centers currently open unblinded interim analysis to be conducted once approximately 400 patients complete their 30-day follow-up; top-line results expected in second half of 2024 recent successful $16 million financing extends company's cash runway through late q3 2024 and beyond expected timing of unblinded interim analysis; potential additional $19 million if warrants are exercised to fund polypid to the start of a planned new drug application submission for d-plex100 petach tikva, israel, feb. 12, 2024 (globe newswire) -- polypid ltd. (nasdaq: pypd) (“polypid” or the “company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled and randomized the 100th patient in its ongoing shield ii phase 3 trial for d-plex100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.
2024-01-31 07:00:00 - Press Release
Polypid To Report Fourth Quarter And Full-year 2023 Financial Results And Operational Highlights On February 14, 2024
Petach tikva, israel, jan. 31, 2024 (globe newswire) -- polypid ltd. (nasdaq: pypd) (“polypid” or the “company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the u.s. financial markets on wednesday, february 14, 2024. the company will host a conference call and webcast at 8:30 am eastern time to discuss the results and provide an update on business operations.
2024-01-04 16:32:00 - Press Release
Polypid Announces Private Placement For $16 Million In Gross Proceeds
Petach tikva, israel, jan. 04, 2024 (globe newswire) -- polypid ltd. (nasdaq: pypd) (“polypid” or the “company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “pipe”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of january 2, 2024 of $4.81 per share.
Latest News
2024-02-28 07:00:00 - GlobeNewsWire
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.
2024-02-19 13:00:25 - Zacks Investment Research
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-02-14 11:13:02 - Seeking Alpha
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
2024-01-31 07:00:00 - GlobeNewsWire
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
2023-11-12 01:08:08 - Seeking Alpha
PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Raghuram Selvaraju - H.C.
2023-09-22 07:00:00 - GlobeNewsWire
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York.
2023-08-09 12:55:44 - Seeking Alpha
PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Conference Call Participants Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. [Operator Instructions].
2023-04-24 07:00:00 - GlobeNewsWire
PolyPid to Participate in Upcoming Investor Conferences
PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:
2023-02-08 13:20:02 - Seeking Alpha
PolyPid Ltd (PYPD) Q4 2022 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q4 2022 Earnings Conference Call February 8, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon Folkes - Cantor Fitzgerald Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions].
2023-01-31 07:00:00 - GlobeNewsWire
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.